Disclosure: None of the authors have any potential conflicts of interest related to the contents of this article.
Antiobesity effect of Gynostemma pentaphyllum extract (actiponin): A randomized, double-blind, placebo-controlled trial
Version of Record online: 5 SEP 2013
Copyright © 2013 The Authors. Obesity published by Wiley Periodicals, Inc. on behalf of The Obesity Society (TOS)
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Volume 22, Issue 1, pages 63–71, January 2014
How to Cite
Park, S.-H., Huh, T.-L., Kim, S.-Y., Oh, M.-R., Tirupathi Pichiah, P.B., Chae, S.-W. and Cha, Y.-S. (2014), Antiobesity effect of Gynostemma pentaphyllum extract (actiponin): A randomized, double-blind, placebo-controlled trial. Obesity, 22: 63–71. doi: 10.1002/oby.20539
Funding agencies: This work was supported by a grant (PF06212-00) from the Plant Diversity Research Center of the 21st Century Frontier Research Program funded by the Ministry of Education, Science and Technology, and by a grant (A111345) from the Korean Health Technology R&D Project from the Ministry of Health and Welfare, Republic of Korea.
Soo-Hyun Park and Tae-Lin Huh contributed equally to this work.
Author Contributions: The authors' responsibilities were as follows: YSC and SWC conceived the study concept and designed the experiments. SHP, SYK, and MRO conducted the experiments. SHP, PBTP, TLH, SWC, and YSC analyzed and interpreted the data, and wrote the manuscript. SWC and YSC had primary responsibility for the final content. All authors read and approved the final version of the manuscript.
- Issue online: 11 JAN 2014
- Version of Record online: 5 SEP 2013
- Accepted manuscript online: 26 JUN 2013 12:56PM EST
- Manuscript Accepted: 27 MAY 2013
- Manuscript Received: 30 NOV 2012
- 1WHO/IASO/IOTF. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Melbourne, Australia: Health Communications Australia, 2000.
- 4Website. FDA. Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events: Food & Drug Administration. [WWW document]. Available at: URL http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830.htm.
- 5Abbott to stop marketing the obesity medicine sibutramin in canada. Abbott News 2010. [WWW document]. Available at: URL http://www.abbott.ca..
- 19KFDA Guideline. Guidelines for Evaluation of the Efficacy of Functional Foods. Korea Food and Drug Administration: Korea, 2012.
- 36European Medicines Agency (EMEA). Guideline on clinical investigation of medicinal products used in weight control. Committee for medicinal products for human use (CHMP) 2006. [WWW document]. Available at: URL http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003213.pdf.
- 37European Medicines Agency (EMEA). Note for guidance on clinical investigation of medical products in the treatment of lipid disorders. Committee for medicinal products for human use (CHMP) 2004. [WWW document]. Available at: URL http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003235.pdf.